Nuvectis Pharma, Inc. (NASDAQ: NVCT) is a Healthcare company (Biotechnology) with a market capitalization of $660M. The Maz Rating grades it against the other companies in its sector.
Nuvectis Pharma, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $19.20, Nuvectis Pharma, Inc. trades at 4.5x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -119.9%, return on invested capital of -41.2% and a free cash flow yield of -6.1%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 9.92. Over the past 52 weeks the share price ranged from $5.77 to $29.28, with a beta of -0.24.
Nuvectis Pharma, Inc. does not currently pay a dividend.
3 Wall Street analyst ratings cover the stock: 3 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.